论文部分内容阅读
肿瘤干细胞已经成为药物递送的一个新靶点。肿瘤干细胞表面表达特异性标志物,其中CD133在胶质瘤肿瘤干细胞中高表达。因此,我们通过将特异性结合CD133的TR短肽修饰到药物递送系统上,来达到靶向递送药物的胶质瘤干细胞的目的。首先,我们将TR短肽与DSPE-PEG连接,构建包载香豆素-6的主被动DSPE-PEG胶束。之后,我们通过荧光激发免疫细胞分选法和肿瘤球培养法分离胶质瘤肿瘤干细胞。通过共聚焦显微镜和流式细胞仪检测发现,肿瘤干细胞对T R修饰的胶束摄取增多,证明TR修饰胶束具有体外靶向性。由此表明,TR修饰胶束有可能提供了针对CD133+肿瘤干细胞的新的治疗策略。
Cancer stem cells have become a new target for drug delivery. Tumor stem cell surface expression specific markers, of which CD133 is overexpressed in glioma tumor stem cells. Therefore, we have achieved the goal of targeting drug-delivered glioma stem cells by modifying the TR peptide that specifically binds CD133 to the drug delivery system. First, we linked the TR short peptide to DSPE-PEG to construct a master-passive DSPE-PEG micelle containing coumarin-6. After that, we isolated glioma tumor stem cells by fluorescence-activated immune cell sorting and tumor ball culture. By confocal microscopy and flow cytometry, it was found that the uptake of T R-modified micelles by tumor stem cells increased, indicating that TR-modified micelles have in vitro targeting. This suggests that TR-modified micelles may provide new therapeutic strategies for CD133 + tumor stem cells.